CHIMERIC THERAPEUTICS
Chimeric Therapeutics is a company developing ground-breaking CAR T cell therapies for solid tumors based on research at the City of Hope Cancer Centre in Los Angeles. The technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor targeting component of the CAR to reprogram T cells and is currently undergoing Phase 1 clinical trials at City of Hope in glioblastoma.
CHIMERIC THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2020-01-01
Address:
Carlton South, Victoria, Australia
Country:
Australia
Website Url:
http://www.chimerictherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+61 3 98245254
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag
Similar Organizations
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.chimerictherapeutics.com Semrush global rank: 5.09 M Semrush visits lastest month: 1.61 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Chimeric Therapeutics"
Home | Chimeric
Chimeric Therapeutics is a results-driven cancer cell therapy company with 3 CAR T & NK cell assets all in Phase 1/1b clinical trials. Chimeric Therapeutic's diversified portfolio includes first …See details»
OUR TEAM - Chimeric Therapeutics
Chimeric Therapeutics is led by a team of cell therapy pioneers and experts who are committed to bringing the promise of cell therapy to life for more patients with cancer.See details»
About | Chimeric
Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.See details»
Chimeric Therapeutics - LinkedIn
Chimeric Therapeutics is the ASX leader in cell therapy. As the only clinical stage, cell therapy biotechnology company in Australia, our focus is on discovering, developing and commercialising...See details»
Chimeric Therapeutics - Crunchbase Company Profile …
Chimeric Therapeutics is a company developing ground-breaking CAR T cell therapies for solid tumors. View contacts for Chimeric Therapeutics to access …See details»
Chimeric Therapeutics - BIO International Convention | BIO - bio.org
Jun 5, 2023 · Chimeric Therapeutics is a clinical stage cell therapy company with encouraging early clinical data in Glioblastoma with CHM 1101 and in HR-MDS/ AML with CHM 0201. …See details»
Chimeric Therapeutics and OncoBay Clinical Form Partnership to …
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company, is pleased to announce that it has entered a strategic partnership with OncoBay …See details»
City of Hope enters licensing agreement with Chimeric to develop …
Chimeric has acquired the exclusive worldwide rights to develop and commercialize certain patents relating to City of Hope’s CLTX-CAR T cells, as well as to further develop the therapy …See details»
Pipeline | Chimeric - Chimeric Therapeutics
With a focus on novel cell therapies for cancer, Chimeric currently has three novel cell therapies in four clinical 1 trials. Each has advanced to human trials. Our first asset, CHM CDH17, is in …See details»
Chimeric Announces Launch of New Phase 1B Glioblastoma …
Jun 5, 2023 · SYDNEY, Australia, June 04, 2023 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), the only clinical stage cell therapy company on the …See details»
CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND …
Oct 31, 2023 · CHM 2101 is a 3 rd generation, novel CDH17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common …See details»
Chimeric enters partnership with WuXi Advanced Therapies
Apr 14, 2022 · Chimeric Therapeutics (ASX:CHM, “Chimeric”) a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has entered …See details»
Chimeric enters strategic manufacturing partnership with WuXi …
Chimeric Therapeutics a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has entered into a strategic manufacturing partnership …See details»
Investor - Chimeric
Chimeric Therapeutics is focused upon delivering results for patients, partners and investors.See details»
Chimeric Therapeutics Takes Cell Therapy From Biotech Dream To …
Dec 27, 2021 · Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer.See details»
Chimeric Therapeutics Ltd (ASX:CHM) Share Price | Morningstar
Company Profile. Business description. Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses …See details»
Chimeric enters strategic manufacturing partnership with
Apr 12, 2022 · Chimeric Therapeutics will leverage WuXi Advanced Therapies’ (“WuXi ATU”) closed loop CAR T platform and other capabilities to accelerate the clinical development of …See details»
Chimeric Therapeutics - Craft
Sep 20, 2024 · Chimeric Therapeutics is a clinical-stage cell therapy company. It offers NK and T cell-derived allogeneic therapies, clinical trials, and other services for solid tumors. See …See details»
T Cell | Chimeric
CHM 1101 (CLTX CAR T) is an optimised first-in-class CAR T cell therapy that uniquely utilises Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its …See details»
Current and Future Roles of Chimeric Antigen Receptor T-Cell …
3 days ago · Importance Advancements in molecular engineering have facilitated the creation of engineered T cells that express synthetic receptors, termed chimeric antigen receptors …See details»